PatientEngagementHIT

Prescription drug spending

76% of Patients Benefit from Drug Price Transparency Technology

February 12, 2019 - Providing point-of-care drug price transparency may be getting closer to a reality, as more providers adopt the technology necessary to view such information, according to a Surescripts report released this week at HIMSS. Price transparency tools are key for reducing the blow of pharmacy sticker shock and helping to identify lower-cost options. “With prescription price...


More Articles

Clinicians Doubt Patient Care Access, Costs Reduction Progress

by Sara Heath

Reducing patient healthcare costs and increasing patient access to care are key priorities in 2019, most clinicians agree, but there isn’t much hope that the industry will achieve these goals, according to a recent poll from...

How Can CMS Address Senior Poverty, Patient Healthcare Costs?

by Sara Heath

Cutting patient healthcare costs will be a key step toward addressing senior poverty, which is ultimately a high priority for the Centers for Medicare & Medicaid Services (CMS), the agency said in a blog post. Late last month, the...

HHS Proposal Reforms Drug Rebates to Reduce Patient Spending

by Sara Heath

HHS has proposed to eliminate drug kickbacks and rebates passed from manufacturer to pharmacy benefits manager (PBM), instead requiring those types of savings to be passed directly to patients. This is a part of the Department’s...

Specialty Drugs Rake in High Out-of-Pocket Costs for Part D Patients

by Sara Heath

Medicare Part D enrollees with serious illness can expect extraordinary out-of-pocket healthcare costs as they seek drugs for their conditions, according to a recent analysis from the Kaiser Family Foundation (KFF). “The findings...

Medicare Part B Drug Plan Could Raise Out-of-Pocket Patient Costs

by Sara Heath

An HHS proposal to shift some Medicare Part B drugs to Medicare Part D may decrease overall drug spending, but it could increase out-of-pocket patient costs, data suggests. The HHS proposal would shift Part B drugs to Part D prescription...

Cerner Collaboration to Drive Drug Price Transparency in the EHR

by Sara Heath

EHR vendor Cerner and CoverMyMeds, a health IT company that focuses on prior authorizations, have partnered to bring point-of-care price transparency to patient and provider. The partnership will put contextualized drug prices in front of...

Using Patient-Provider Communication for Antibiotic Stewardship

by Sara Heath

As the healthcare industry continues to explore the meaning of quality in healthcare, an examination of antibiotic stewardship may come to the forefront. But as antibiotic prescriptions are shown to correlate with patient satisfaction,...

Part D Drug Price Proposal Could Limit Patient Access to Care

by Sara Heath

Utilization management strategies such as formulary tiers and copayments serve as significant barriers to Medicare Part D drugs for many patients managing serious illness, according to a new report conducted by Avalere Health on behalf of...

CMS Drug Price Proposal Aims to Cut Out-of-Pocket Patient Spending

by Sara Heath

CMS has proposed a new drug price model for Medicare Parts C and D that will ideally reduce out-of-pocket patient spending. The policies, which if approved would go into effect in 2020, would impact Medicare Advantage and Medicare Parts C...

Health Payer Incentive Program Supports Patient Drug Price Shopping

by Sara Heath

UnitedHealthcare has announced plans to offer a rewards program for patients who seek out lower-cost drug options. This comes as part of the health plan’s efforts to put a cap on prescription drug spending and empower patients to...

HHS Drug Payment Proposal May Cut Out-of-Pocket Patient Costs

by Sara Heath

HHS has unveiled the International Pricing Index (IPI), a proposed payment model that would allow Medicare to set drug prices at rates closer to those in other developed nations. This move has the potential to reduce out-of-pocket patient...

Breaking Down HHS Drug Advertisement, Price Transparency Proposal

by Sara Heath

A storm is brewing between the Department of Health & Human Services and the pharmaceutical industry, as experts on both sides debate drug advertisements and requirements for consumer-centered price transparency. Causing the debate is...

Gag Clause Bills Signed into Law, Improves Healthcare Transparency

by Sara Heath

President Trump has signed into law two bills that prohibit pharmacy gag clauses, or the practice of prohibiting pharmacy and healthcare transparency. The laws – one targeted at Medicare plans and one for private and...

Patients Say US Drug Prices “Unreasonable,” Need Gov’t Attention

by Sara Heath

Seventy-seven percent of patients believe US drug prices are “unreasonable,” but most don’t approve of current government solutions to combat high drug costs, according to a recent survey conducted by NORC at the...

How to Improve PBM Practices to Boost Patient Access to Care

by Sara Heath

Pharmacy benefit manager (PBM) companies need to retool their strategies to improve cancer patient access to care, according to a recent position paper published by the American Society of Clinical Oncology (ASCO). The paper, published on...

Senate Moves Toward Drug Price Transparency in Consumer Ads

by Sara Heath

Better drug price transparency in direct-to-consumer marketing plays a key role in a funding package that has recently passed in the Senate. In a bipartisan amendment funding both the Health, Education, Labor, and Pensions (HELP) and...

How Medication Overutilization Drives Out-of-Pocket Healthcare Costs

by Sara Heath

Medication overutilization is costing patients thousands of dollars in out-of-pocket healthcare costs, according to a recent report from the AARP. Specifically, unnecessarily prolonged prescription of dementia medications is running up a...

Retail Chain Deals to Improve Patient Care Access, Care Coordination

by Sara Heath

A new partnership between healthcare payer Anthem and Walmart will improve patient care and more affordable access to over-the-counter (OTC) medications. The program, set to launch in January 2019, will allow beneficiaries of...

Patient Groups Advocate Patient Access to Care in Drug Blueprint

by Sara Heath

The Department of Health & Human Services’ drug pricing blueprint presents numerous opportunities to lower drug prices, but the agency should be wary of changes that would restrict patient access to care, the American Cancer...

X

Sign up for our free newsletter:

Our privacy policy


no, thanks

Continue to site...